RSPH10B

Across TCGA pan-cancer cohorts, RSPH10B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RSPH10B data layer compared with 23 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher RSPH10B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RSPH10B expression acts as an unfavorable survival marker.

THCA, THYM, and GBM are the cancer types where RSPH10B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	DFS	Median	All	0.095	0.896	<.001	18	view →
THYM	DFS	Median	All	0.123	0.871	<.001	12	view →
GBM	DFS	Median	All	0.048	0.257	.001	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RSPH10B–THCA (DFS)

Open the THCA breakdown →